{
  "sector": "Healthcare",
  "fullTimeEmployees": 285,
  "longBusinessSummary": "Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. It offers Ganovo, a direct-acting anti-viral agent for the treatment of hepatitis C virus (HCV); Pegasys, a pegylated interferon for Hepatitis B and C virus; and Ravidasvir, a pan-genotypic NS5A inhibitor for the treatment of HCV. Its products pipeline includes ASC22, a PD-L1 single domain antibody fragment crystallizable fusion, which is in Phase II trial for the treatment of chronic Hepatitis B infection; ASC40, a Phase II-ready fatty acid synthase inhibitor for the treatment of non-alcoholic steatohepatitis (NASH); and ASC41, an oral THR-Ã agonist for the treatment of NASH. The company's products also comprise ASC09, a protease inhibitor that has completed Phase IIA clinical trial to treat human immunodeficiency virus type-1 infections; ASC06, which has completed Phase I clinical trial for treating liver cancer; and ASC21, a HCV NS5B polymerase inhibitor. In addition, it is developing therapies that are in pre-clinical trials for the treatment of hepatitis B virus and NASH. The company was incorporated in 2014 and is headquartered in Hangzhou, the People's Republic of China.",
  "city": "Hangzhou",
  "country": "China",
  "companyOfficers": [],
  "website": "http://www.ascletis.com",
  "maxAge": 1,
  "address1": "Building 3",
  "fax": "86 571 8538 9730",
  "industry": "Biotechnology",
  "address2": "12th Floor No. 371 Mingxing Road, HIPARK Xiaoshan District",
  "previousClose": 0.38,
  "regularMarketOpen": 0.38,
  "twoHundredDayAverage": 0.40358695,
  "trailingAnnualDividendYield": null,
  "payoutRatio": 0,
  "volume24Hr": null,
  "regularMarketDayHigh": 0.38,
  "navPrice": null,
  "averageDailyVolume10Day": 1904,
  "totalAssets": null,
  "regularMarketPreviousClose": 0.38,
  "fiftyDayAverage": 0.3839394,
  "trailingAnnualDividendRate": null,
  "open": 0.38,
  "averageVolume10days": 1904,
  "expireDate": null,
  "yield": null,
  "algorithm": null,
  "dividendRate": null,
  "exDividendDate": null,
  "beta": 0.755229,
  "circulatingSupply": null,
  "startDate": null,
  "regularMarketDayLow": 0.38,
  "priceHint": 4,
  "currency": "USD",
  "regularMarketVolume": 14475,
  "lastMarket": null,
  "maxSupply": null,
  "openInterest": null,
  "marketCap": 399577600,
  "volumeAllCurrencies": null,
  "strikePrice": null,
  "averageVolume": 505,
  "priceToSalesTrailing12Months": null,
  "dayLow": 0.38,
  "ask": null,
  "ytdReturn": null,
  "askSize": null,
  "volume": 14475,
  "fiftyTwoWeekHigh": 0.65,
  "forwardPE": null,
  "fromCurrency": null,
  "fiveYearAvgDividendYield": null,
  "fiftyTwoWeekLow": 0.3,
  "bid": null,
  "tradeable": false,
  "dividendYield": null,
  "bidSize": null,
  "dayHigh": 0.38,
  "exchange": "PNK",
  "shortName": "ASCLETIS PHARMA INC",
  "longName": "Ascletis Pharma Inc.",
  "exchangeTimezoneName": "America/New_York",
  "exchangeTimezoneShortName": "EST",
  "isEsgPopulated": false,
  "gmtOffSetMilliseconds": "-18000000",
  "underlyingSymbol": null,
  "quoteType": "EQUITY",
  "symbol": "ASCLF",
  "underlyingExchangeSymbol": null,
  "headSymbol": null,
  "messageBoardId": "finmb_574413177",
  "uuid": "ae12396b-e075-3e94-9aa4-3adaf774d9f9",
  "market": "us_market",
  "annualHoldingsTurnover": null,
  "enterpriseToRevenue": null,
  "beta3Year": null,
  "profitMargins": -0.77153,
  "enterpriseToEbitda": null,
  "52WeekChange": null,
  "morningStarRiskRating": null,
  "forwardEps": null,
  "revenueQuarterlyGrowth": null,
  "sharesOutstanding": 1098780032,
  "fundInceptionDate": null,
  "annualReportExpenseRatio": null,
  "bookValue": null,
  "sharesShort": null,
  "sharesPercentSharesOut": null,
  "fundFamily": null,
  "lastFiscalYearEnd": 1577750400,
  "heldPercentInstitutions": 0.023359999,
  "netIncomeToCommon": null,
  "trailingEps": null,
  "lastDividendValue": null,
  "SandP52WeekChange": null,
  "priceToBook": null,
  "heldPercentInsiders": 0.6732,
  "nextFiscalYearEnd": 1640908800,
  "mostRecentQuarter": 1593475200,
  "shortRatio": null,
  "sharesShortPreviousMonthDate": null,
  "floatShares": 339118559,
  "enterpriseValue": 395728576,
  "threeYearAverageReturn": null,
  "lastSplitDate": null,
  "lastSplitFactor": null,
  "legalType": null,
  "morningStarOverallRating": null,
  "earningsQuarterlyGrowth": null,
  "dateShortInterest": null,
  "pegRatio": null,
  "lastCapGain": null,
  "shortPercentOfFloat": null,
  "sharesShortPriorMonth": null,
  "category": null,
  "fiveYearAverageReturn": null,
  "regularMarketPrice": 0.38,
  "logo_url": "https://logo.clearbit.com/ascletis.com"
}